title: Middle East respiratory syndrome: obstacles and prospects for vaccine development.
abstract: The recent emergence of Middle East respiratory syndrome (MERS) highlights the need to engineer new methods for expediting vaccine development against emerging diseases. However, several obstacles prevent pursuit of a licensable MERS vaccine. First, the lack of a suitable animal model for MERS complicates the in vivo testing of candidate vaccines. Second, due to the low number of MERS cases, pharmaceutical companies have little incentive to pursue MERS vaccine production as the costs of clinical trials are high. In addition, the timeline from bench research to approved vaccine use is 10 years or longer. Using novel methods and cost-saving strategies, genetically engineered vaccines can be produced quickly and cost-effectively. Along with progress in MERS animal model development, these obstacles can be circumvented or at least mitigated.
authors: Emerging Viral Pathogens Section, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Fort Detrick, Frederick, MD, USA.
authors: Amy B
authors: AB
authors: Papaneri
authors: Reed F
authors: RF
authors: Johnson
authors: Jiro
authors: J
authors: Wada
authors: Laura
authors: L
authors: Bollinger
authors: Peter B
authors: PB
authors: Jahrling
authors: Jens H
authors: JH
authors: Kuhn
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D018352:Coronavirus Infections / Q000517:prevention & control*; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000191:economics / Q000639:trends; D004353:Drug Evaluation, Preclinical / Q000191:economics / Q000379:methods; D006801:Humans; D014765:Viral Vaccines / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D014765:Viral Vaccines
keywords: Coronaviridae; MERS-CoV; Middle East respiratory syndrome; Nidovirales; betacoronavirus; coronavirus; nidovirus